ERBB2 and neoplasm: The mean follow-up duration of our patients was 5.8 ± 3.0 years (range: 0.7-17.4). Univariate analysis for correlation between pathological response and clinicopathological parameters (Table 2) revealed that ER expression (p <0.001), PR expression (p=0.005), HER-2 status (p=0.02), IHC-based molecular subtypes (p <0.001), tumor T stage (p=0.04), tumor N stage (p=0.01), and Ki67 (p=0.03) were significantly associated with tumor pathological response.